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Intravenous Iron and Maintenance Hemodialysis
To the Editor: In the Proactive IV Iron Therapy 
in Haemodialysis Patients (PIVOTAL) trial con-
ducted by Macdougall et al. (Jan. 31 issue),1 the 
reactive, low-dose iron regimen (in which intra-
venous iron was administered if the ferritin con-
centration was <200 μg per liter or the transferrin 
saturation was <20%) resulted in iron deficiency 
anemia and harmed the patients. Nearly half the 
patients had a transferrin saturation of less than 
20%, and approximately 25% of the patients had 
a serum ferritin concentration of less than 100 μg 
per liter. This culminated in persistent thrombo-
cytosis and a drop in the hemoglobin level. De-
spite the protocol mandating that the hemoglo-
bin level be maintained between 10 and 12 g per 
deciliter with the administration of an erythro-
poietin-stimulating agent, nearly 25% of the pa-
tients had a hemoglobin level of less than 10 g per 
deciliter in the first 9 to 12 months of the trial.
The drop in hemoglobin levels resulted in a 
higher incidence of transfusion, as well as a higher 
incidence of recurrent cardiovascular events, in 
the low-dose group than in the high-dose group. 
Whereas the median dose of erythropoietin-
stimulating agent did not decrease in the high-
dose group, it increased in the low-dose group. 
The between-group difference in the median dose 
of erythropoietin-stimulating agent was there-
fore due to increased use in the low-dose group. 
These data suggest that iron deficiency anemia 
in patients undergoing hemodialysis results in 
the increased use of erythropoietin-stimulating 
agents and transfusions and an increased inci-
dence of recurrent heart-failure events.
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To the Editor: Macdougall et al. report the highly 
anticipated results of the PIVOTAL trial, which 
showed that the use of erythropoiesis-stimulat-
ing agents and blood transfusions was substan-
tially lower with a high-dose iron sucrose regi-
men than with a low-dose iron sucrose regimen 
in patients undergoing hemodialysis. The trial 
showed the noninferiority of the high-dose regi-
men to the low-dose regimen with respect to the 
risks of death, major adverse cardiovascular 
events, and infection. However, we would like to 
emphasize that currently, at least in the Nether-
lands, the use of iron sucrose is no longer daily 
practice, since nearly all dialysis centers have 
switched to newer (and generally considered to 
be better) intravenous iron preparations, such as 
ferric carboxymaltose or iron isomaltoside.1-3
Recently, our group found that switching from 
iron sucrose to ferric carboxymaltose in patients 
undergoing hemodialysis resulted in improved 
iron status and hemoglobin levels and less use 
of erythropoiesis-stimulating agents in patients 
who were administered less iron.4 Hence, we 
anticipate that by using newer intravenous iron 
preparations, the currently major identified re-
sults (i.e., use of lower doses of erythropoiesis-
stimulating agents and fewer blood transfusions) 
will be more apparent.
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To the Editor: In their article, Macdougall et al. 
seem to claim that, in patients undergoing hemo-
dialysis, intravenous iron administration at a high 
dose is safe and is associated with lower doses of 
erythropoiesis-stimulating agent than a low iron 
dose in patients undergoing hemodialysis. In our 
view, the authors merely found no significant 
differences in the risks of death, major cardio-
vascular events, and infection between the high-
dose group and the low-dose group. However, a 
substantial amount of iron was administered, 
even in the low-dose group. One could conclude 
that the risk associated with intravenous iron is 
the same among patients whose ferritin concen-
trations are more than 100 to 200 μg per liter as 
it is among patients with renal anemia who are 
undergoing hemodialysis. In an observational 
study, we found that patients with a higher fer-
ritin concentration (≥100 μg per liter) had a 
higher risk of cardiovascular and infectious dis-
eases than patients with a lower ferritin concen-
tration (<100 μg per liter).1 We would like to re-
mind readers that high ferritin concentrations 
are associated with a rise in the hepcidin level, 
which could hamper iron reutilization and induce 
hyporesponsiveness to erythropoiesis-stimulating 
agents.2 Given the threshold for ferritin concen-
tration for these risks, it would be useful to ex-
plore well-balanced therapy with erythropoiesis-
stimulating agents and iron for the treatment of 
renal anemia.
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To the Editor: The trial by Macdougall et al. 
compared the administration of high-dose iron 
sucrose with low-dose iron sucrose in patients 
undergoing hemodialysis. Patients in the high-
dose group underwent fewer blood transfusions 
and received lower doses of erythropoiesis-stim-
ulating agents to maintain target hemoglobin 
levels than those in the low-dose group. The two 
groups were well balanced in various aspects. 
However, the use of angiotensin-converting–
enzyme (ACE) inhibitors or angiotensin-receptor 
blockers (ARBs) was lower in the high-dose 
group than in the low-dose group (276 of 1093 
patients [25.3%] vs. 318 of 1048 patients [30.3%], 
P = 0.009).
Although this trial is informative, we think 
that different use of ACE inhibitors and ARBs 
may have effects on the results. Although the 
idea is not universally accepted, studies have 
shown that the use of ACE inhibitors or ARBs is 
associated with anemia in patients with chronic 
kidney disease.1-3 The use of ACE inhibitors and 
ARBs may be a component of hyporesponsive-
ness to erythropoiesis-stimulating agents in pa-
tients with chronic kidney disease.4 Therefore, we 
would suggest that the low use of erythropoiesis-
stimulating agents and low incidence of transfu-
sion may be attributable in part to the low per-
centage of patients who used ACE inhibitors and 
ARBs. We think that it would be better if the 
analysis had been adjusted for the use of ACE 
inhibitors and ARBs.
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The authors reply: Given the global variation 
in the use of intravenous iron in routine prac-
tice,1 it is enlightening to receive perspectives 
from the United States, the Netherlands, Japan, 
and Turkey, particularly the opposing views from 
the United States and Japan. These views reflect 
the extremes of iron use worldwide.1
We agree with Agarwal that many patients in 
the low-dose group of the trial had borderline or 
overt iron deficiency, which was harmful. How-
ever, the ferritin and transferrin saturation 
thresholds for iron administration in this group 
were consistent with European guidelines2 and 
exceeded the recommendations from Japan,3 even 
though many physicians in the United States 
adopt iron-management strategies that are con-
sistent with those in the high-dose group. Re-
cently, Agarwal expressed concerns about exac-
erbating cardiovascular events and infections 
with intravenous iron4; perhaps the results of 
our trial have induced reconsideration on this 
point.
The claim by Eisenga et al. that the use of 
newer intravenous iron preparations may pro-
duce positive outcomes similar to those seen in 
our trial with a less pronounced high-dose regi-
men may be true. However, in the absence of 
randomized, controlled trials, such claims should 
be tempered.
Nakanishi and Kuragano comment that pa-
tients in the low-dose group still received a 
“substantial amount of iron,” which may be true 
by Japanese standards but is certainly not the case 
for the rest of the world1 and is inconsistent with 
the comments of Agarwal (see above). Further-
more, we suggest that the concern of Nakanishi 
and Kuragano that the risks of cardiovascular and 
infectious complications with intravenous iron 
above a range of ferritin concentration of 100 
to 200 μg per liter, as compared with less than 
100 μg per liter, seems misguided, given that 
this concern is based on observational data.
Afsar and colleagues suggest that our analy-
sis should be adjusted because of a significant 
difference in the baseline use of ACE inhibitors 
and ARBs. First, we note that post hoc adjust-
ment for imbalances in baseline characteristics 
can lead to biased estimation of treatment effects 
and is not a recommended approach, as ex-
plained by the late Doug Altman.5 The adjusted 
analysis for our primary end point provides an 
estimated hazard ratio of 0.83, with a 95% con-
fidence interval of 0.71 to 0.97, and a P value for 
superiority of 0.02 for the comparison of the 
proactive, high-dose iron regimen with the re-
active, low-dose regimen. However, we would 
urge readers to ignore this apparently improved 
result and to focus on the results that were 
based on our prespecified analysis strategy.
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